

## REFERENCES

### 1. REFERENCE INDEX

#### **CORRELATION OF PK PARAMETERS WITH VIROLOGIC RESPONSE (PUBLISHED LITERATURE):**

2. P. Clevenbergh, J. Durant, R. Garraffo, P. Halfon, P. del Giudice, P. Simonet, N. Montagne, CAB Boucher, JM Schapiro, and P. Dellamonica, "Persisting Long Term Benefit Of Genotypic Guided Treatment In HIV Infected Patients Failing HAART And Importance Of Protease Inhibitor Plasma Levels. Viradapt Study, Week 48 Follow Up and Pharmacological Data" (source not provided)
3. "Pharmacokinetic Enhancement of Other Protease Inhibitors with Ritonavir" from medscape.com  
  
P. Lorenzi, S. Yerly, K. Abderrakim, M. Fathi, O. T. Rutschmann, J. von Overbeck, D. Leduc, L. Perrin, B. Hirschel and the Swiss HIV Cohort Study, "Toxicity, Efficacy, Plasma Drug Concentrations and Protease Mutations In Patients with Advanced HIV Infection Treated with Ritonavir Plus Saquinavir", AIDS 1997;11(12): F95-F99
4. R. L. Murphy, JP. Sommadossi, M. Lamson, D.B. Hall, M. Myers, and A. Dusek, "Antiviral Effect and Pharmacokinetic Interaction between Nevirapine and Indinavir in Persons Infected with Human Immunodeficiency Virus Type I", Journal of Infectious Diseases 1999; 179:1116-23
5. M. F. Para, P. Meehan, J. Holden-Wiltse, M. Fischl, G. Morse, R. Shafer, L. M. Demeter, K. Wood, T. Nevin, N. Virani-Ketter, and W. W. Freimuth for the AIDS Clinical Trials Group Protocol 260 Team, "ACTG 260: a Randomized, Phase I-II, Dose-Ranging Trial of the Anti-Human Immunodeficiency Virus Activity of Delavirdine Monotherapy", Antimicrobial Agents and Chemotherapy, June 1999; 43(6): 1373-1378
6. R. Gieschke, B. Fotteler, N. Buss and JL. Steimer, "Relationships Between Exposure to Saquinavir Monotherapy and Antiviral Response in HIV-Positive Patients", Clin. Pharmacokinet 1999; 37(1): 75-86
7. G. Gatti, A. Di Biagio, R. Casazza, C. De Pascalis, M. Bassetti, M. Cruciani, S. Vella, and D. Bassetti, "The Relationship Between Ritonavir Plasma Levels And Side-Effects: Implications For Therapeutic Drug Monitoring", AIDS 1999; 13(15): 2083-2089
8. D. S. Stein, D. G. Fish, J. A. Bilello, S. L. Preston, G. L. Martineau and G. L. Drusano, "A 24-Week Open Label Phase I/II Evaluation of the HIV Protease Inhibitor MK-639 (Indinavir)", AIDS 1996; 10(5): 485-492
9. M. Harris, C. Durakovic, S. Rae, J. Raboud, S. Fransen, A. Shillington, B. Conway, and J. S. G. Montaner, "A Pilot Study of Nevirapine, Indinavir, and Lamivudine among Patients with Advanced Human Immunodeficiency Virus

Disease Who Have Had Failure of Combination Nucleoside Therapy”, Journal of Infectious Diseases 1998; 177:1514-20

10. C. V. Fletcher, R. C. Brundage, R. P. Remmel, L. M. Page, D. Weller, N. R. Calles, C. Simon, and M.W. Kline, “ Pharmacologic Characteristics of Indinavir, Didanosine, and Stavudine in Human Immunodeficiency Virus-Infected Children Receiving Combination Therapy”, Antimicrobial Agents and Chemotherapy 2000; 44(4): 1029-1034
11. E. P. Acosta, K. Henry, L. Baken, L. M. Page, and C.V. Fletcher, “Indinavir Concentrations and Antiviral Effect”, Pharmacotherapy 1999: 19(6): 708-712

**12. CORRELATION OF PK PARAMETERS WITH VIROLOGIC RESPONSE AND TOXICITY (ABSTRACTS):**

#42259 R. M. W. Hoetelmans, M. H. E. Reijers, G. F. Weberling, S. Furriaans, and F. M. A. Lange, “The Rate of Decline of HIV-1 RNA in Plasma Correlates with Nelfinavir Concentrations in Plasma” (source not provided)

#42261 R. M. W. Hoetelmans, R. P. G. Heeswijk, Van, P. L. Meenhorst, F. W. Mulder, W. A. Scheele, and F. H. Beijnen, “Plasma Concentrations of Saquinavir (SQV) Determine HIV-1 RNA Response Over A 48-Week Period” (source not provided)

#5.3 D. M. Burger, A. M.C. Van Rossum, P. W. H. Hugen, S.P. M. Geelen, and R. De Groot for the Dutch Study Group for Children with HIV Infection, “The Indinavir (IDV) Area-Under-The-Plasma-Concentration-Time-Curve (AUC) in HIV-1-Infected Children Should Be Above 20mg/L.h to Obtain an Optimal Virological Response” (source not provided)

#5.4 G. Gatti, A. Di Biagio, M. Mastropasqua, M. Bassetti, S. Vella, D. Bassetti and the ISS-IP-1 PK/PD study group, “ The Relationship between Systemic Exposure to Indinavir and Virologic Efficacy”(source not provided)

#12304 B. Kerr, Y. Pithavala, M. Zhang, M. Knowles, R. Daniels, and R. Anderson, “Virologic Response-Plasma Drug Concentration Relationship in Phase III Study of Nelfinavir Mesylate (VIRACEPT)”, 12<sup>th</sup> World AIDS Conference Programme Search

#12372 J. Dieleman, I. C. Gyssens, M.E.M. van der Ende, S. de Marie, and D. M. Burger, “Urologic Complaints in Relation to Indinavir Plasma Levels in HIV-Infected Patients”, 12<sup>th</sup> World AIDS Conference Programme Search

**13. PK PARAMETERS IN THE SETTING OF PHARMACOLOGIC ENHANCEMENT (ABSTRACTS AND PUBLISHED LITERATURE):**

# 362 A. Saah, G. Winchell, M. Seniuk, D. Mehrotra, and P. Deutsch, “Multiple-dose Pharmacokinetics (PK) and Tolerability of Indinavir (IDV)-Ritonavir (RTV)

Combinations In Healthy Volunteers (Merck 078)", 6<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, 1999, Chicago, Illinois

#363 D. M. Burger, P. W. H. Hugen, J. M. Prins, M. E. Van De Ende, P. Reiss, and J. M. A. Lange, " Pharmacokinetics of Indinavir/ Ritonavir 800/ 100 mg BID regimen", 6<sup>th</sup> Conference on Retroviruses and Opportunistic Infections, 1999, Chicago, Illinois

14. A. Hsu, G. R. Granneman, G. Cao, L. Carothers, A. Japour, T. El-Shourbagy, S. Dennis, J. Berg, K. Erdman, J. M. Leonard, and E. Sun, " Pharmacokinetic Interaction between Ritonavir and Indinavir in Healthy Volunteers", Antimicrobial Agents and Chemotherapy, 1998; 42(11): 2784-2791

15. N. Shulman, A. Zolopa, D. Havlir, and J. Gallant, " Ritonavir Intensification..." (poster presentation)

R. M. E. van Praag, G. J. Weverling, P. Portegies, S. Jurriaans, X. J. Zhou, M.L. Turner-Folsy, J. P. Somadossi, D. M. Burger, R. M. W. Hoetelmans, J. M. A. Lange and J. M Prins, "Enhanced Penetration of Indinavir (IDV) in Cerebrospinal Fluid and Semen after Addition of Low-Dose Ritonavir (RTV)", (poster presentation)

16. **GUIDANCE FOR INDUSTRY: PROVIDING CLINICAL EVIDENCE OF EFFECTIVENESS FOR HUMAN DRUG AND BIOLOGICAL PRODUCTS:**

Guidance for Industry: Providing Clinical Evidence of Effectiveness for Human Drug and Biological Products, May 1998; Clinical 6: 1-20

17. **21 CFR 320.23 REFERENCE:**

21 CFR 320.23 Basis for demonstrating in vivo bioavailability or bioequivalence